CWM
ATHE

Cranbrook Wealth Management’s Alterity Therapeutics ATHE Stock Holding History

Cranbrook Wealth Management’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Buy
+1
New +$4 ﹤0.01% 406

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $262M AUM 60.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cranbrook Wealth Management's ATHE Position: Q2 2026 in Review

Cranbrook Wealth Management opened a new position in Alterity Therapeutics (ATHE) in Q2 2026: 1 share worth $6. The stake represents ﹤0.01% of the portfolio and ranks #406 among its holdings.

22 funds tracked by Wall St. Rank hold ATHE as of Q2 2026.

  • Cranbrook Wealth Management held 1 share of Alterity Therapeutics worth $6 as of Q2 2026.
  • Alterity Therapeutics was a new Cranbrook Wealth Management position in Q2 2026.
  • Alterity Therapeutics made up ﹤0.01% of Cranbrook Wealth Management's portfolio in Q2 2026, its #406 holding.
  • 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2026.

Based on Cranbrook Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.